ZBH · XBRL financial data

Zimmer Biomet Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZBH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	7,025	7,836	6,940	7,394	7,679	8,232
Cost of goods and services sold	2,128	2,341	2,020	2,084	2,191	2,494
Selling, general and administrative	3,178	3,324	2,762	2,839	2,930	3,257
Operating income (loss)	(88)	780	696	1,278	1,286	1,098
Other income (expense)	25	12	(128)	(9)	(31)	26
Income tax expense (benefit)	(137)	16	112	42	131	126
Net income (loss)	(139)	402	231	1,024	904	705
Earnings per share, basic USD per share	(0.67)	1.93	1.10	4.91	4.45	3.56
Earnings per share, diluted USD per share	(0.67)	1.91	1.10	4.88	4.43	3.55
Weighted average shares, basic millions of shares	207	209	210	209	203	198
Weighted average shares, diluted millions of shares	207	210	210	210	204	199

Fiscal years (ZBH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	802	479	376	416	526	592
Accounts receivable	1,453	1,405	1,382	1,442	1,481	1,704
Inventory	2,451	2,395	2,147	2,385	2,235	2,286
Prepaid and other current assets	378	278	325	366	430	537
Total current assets	5,083	4,885	4,427	4,610	4,672	5,120
Property and equipment, net	2,048	2,017	1,873	2,060	2,049	2,207
Right-of-use asset	275	271	196	204	214	204
Goodwill	9,262	9,192	8,580	8,819	8,951	9,947
Total assets	24,418	23,456	21,066	21,497	21,365	23,092
Accounts payable	330	351	354	411	195	303
Accrued liabilities	890	735	582	628	734	835
Current portion of long-term debt	500	1,605	544	900	863	587
Total current liabilities	2,557	3,468	2,358	2,857	2,451	2,584
Long-term debt	7,627	5,464	5,152	4,868	5,342	6,932
Lease liability, non-current	218	220	167	174	190	176
Total liabilities	12,218	10,790	9,039	9,009	8,889	10,386
Retained earnings	10,087	10,292	9,559	10,385	11,095	11,611
Total stockholders' equity	12,194	12,661	12,020	12,481	12,468	12,698
Total liabilities and equity	24,418	23,456	21,066	21,497	21,365	23,092
Common shares outstanding (cover page) millions of shares	208	209	209	205	199	196

Fiscal years (ZBH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(139)	402	231	1,024	904	705
Stock-based compensation	80	85	105	100	101	90
Depreciation and amortization	1,033	1,067	926	952	996	1,094
Net cash from operating activities	1,205	1,499	—	1,582	1,499	1,697
Purchases of property and equipment	118	172	188	291	204	225
Net cash from investing activities	(614)	(504)	—	(779)	(888)	(1,976)
Share repurchases	—	—	126	692	868	487
Dividends paid	199	200	201	201	196	190
Net cash from financing activities	(422)	(1,306)	—	(764)	(485)	326
Net change in cash	184	(324)	(103)	40	110	66

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Zimmer Biomet Holdings	410	2,177	448*	190.7M	Q2 FY26 10-QJun 30, 2026
Baxter International	1,975	2,976	558*	517.3M	Q3 FY26 10-QSep 30, 2026
West Pharmaceutical Services	464	875	190*	69.7M	Q3 FY26 10-QSep 30, 2026
Insulet	535	802	88*	69.4M	Q2 FY26 10-QJun 30, 2026
Hologic	2,168	1,048	230	223.2M	Q1 FY26 10-QDec 27, 2025
STERIS	482	1,493	367	97.5M	Q1 FY27 10-QJun 30, 2026
Solventum	403	2,209	227*	170.2M	Q2 FY26 10-QJun 30, 2026
Medline	2,327	7,685	715*	not reported	Q2 FY26 10-QJun 27, 2026
Align Technology	1,103	1,056	193*	71.0M	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.